NOTE 9 – STOCK WARRANTS AND COMPENSATION

On September 12, 2022, the Company entered into agreements with members of the Board and consultants for services to be performed. As consideration therefore, the Company granted those individuals stock warrants to purchase an aggregate of 33,150,000 shares of common stock. The warrants generally vest over a three-year to five-year term and expire three to five years from the vesting date. The warrants were valued using the Black-Scholes option pricing model under the assumptions as found in the table below.

On November 1, 2022, the Company entered into an agreement with a consultant for services to be performed. As consideration therefore, the Company granted the consultant stock warrants to purchase 100,000 shares of common stock. The warrants vest over a one-year term. The warrants were valued using the Black-Scholes option pricing model under the following assumptions as found in the table below.

On November 3, 2022, the Company entered into an agreement with a consultant for services to be performed. As consideration therefore, the Company granted the consultant stock warrants to purchase 5,000,000 shares of common stock. The warrants vest over a three-year term. The warrants were valued using the Black-Scholes option pricing model under the following assumptions as found in the table below.

On December 29, 2022, the Company entered into an agreement with Ross Sklar, for 285,714 warrants to purchase shares of common stock to be issued as a funding fee for the $2,000,000 secured promissory note (see Note 7). The warrants were valued using the Black-Scholes option pricing model under the following assumptions as found in the table below.

On March 3, 2023, the Company entered into an agreement with Ross Sklar, for 114,286 warrants to purchase shares of Class A common stock to be issued as a funding fee for the $800,000 secured promissory note (see Note 7). The warrants were valued using the Black-Scholes option pricing model under the following assumptions as found in the table below.

On June 1, 2023, the Company entered into an agreement with a consultant for services to be performed. As consideration therefore, the Company granted the consultant stock warrants to purchase 150,000 shares of common stock. The warrants vest over a three-year term. The warrants were valued using the Black-Scholes option pricing model under the following assumptions as found in the table below.

FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES

A summary of the status of the Company’s outstanding stock warrants and changes during the periods is presented below:

SCHEDULE OF OUTSTANDING STOCK WARRANTS AND CHANGES

The fair value of stock warrants granted and vested during the three months ended September 30, 2023 was zero and $923,185 respectively. The fair value of stock warrants granted and vested during the nine months ended September 30, 2023 was $32,723 and $1,215,139 respectively.

The fair value of stock warrants granted and vested during the three months ended September, 2022 was $4,088,769 and $74,580 respectively. The fair value of stock warrants granted and vested during the nine months ended September 30, 2022 was $4,088,769 and $125,277 respectively.

The following table summarizes information about stock warrants to purchase shares of the Company’s common stock outstanding and exercisable as of September 30, 2023:

SCHEDULE OF EXERCISABLE WARRANTS

The compensation expense attributed to the issuance of the stock warrants is recognized as they are vested.

Total compensation expense related to the stock warrants was $396,151 and $60,600 for the three months ended September 30, 2023 and 2022, respectively. Total compensation expense related to the stock warrants was $1,196,430 and $136,940 for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $3,147,705 in future compensation cost related to non-vested stock warrants.

The aggregate intrinsic value as of September 30, 2023 is $52,000 for total outstanding and exercisable warrants, which was based on our estimated fair value of the common stock of $0.14, had all warrant holders exercised their warrants as of that date, net of the aggregate exercise price.